TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment...
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
About this item
Full title
Author / Creator
Frantz, Robert P. , Benza, Raymond L. , Channick, Richard N. , Chin, Kelly , Howard, Luke S. , McLaughlin, Vallerie V. , Sitbon, Olivier , Zamanian, Roham T. , Hemnes, Anna R. , Cravets, Matt , Bruey, Jean-Marie , Roscigno, Robert , Mottola, David , Elman, Erin , Zisman, Lawrence S. and Ghofrani, Hossein-Ardeschir
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Aberrant kinase signaling that involves platelet-derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c-KIT) pathways may be responsible for vascular remodeling in pulmonary arterial hypertension. Targeting these specific pathways may potentially reverse the pathological inflammati...
Alternative Titles
Full title
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e7c6ee3ea34a41f89721a2c6c04b54de
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e7c6ee3ea34a41f89721a2c6c04b54de
Other Identifiers
ISSN
2045-8940,2045-8932
E-ISSN
2045-8940
DOI
10.1177/20458940211057071
